Curis, Inc. (CRIS)
- Previous Close
5.01 - Open
5.01 - Bid --
- Ask --
- Day's Range
5.00 - 5.12 - 52 Week Range
3.80 - 17.49 - Volume
24,240 - Avg. Volume
47,037 - Market Cap (intraday)
30.194M - Beta (5Y Monthly) 3.32
- PE Ratio (TTM)
-- - EPS (TTM)
-8.17 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.50
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
www.curis.comRecent News: CRIS
View MorePerformance Overview: CRIS
Trailing total returns as of 10/9/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRIS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRIS
View MoreValuation Measures
Market Cap
30.01M
Enterprise Value
5.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.85
Price/Book (mrq)
4.32
Enterprise Value/Revenue
0.51
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.97%
Return on Equity (ttm)
-372.67%
Revenue (ttm)
10.16M
Net Income Avi to Common (ttm)
-47.57M
Diluted EPS (ttm)
-8.17
Balance Sheet and Cash Flow
Total Cash (mrq)
28.36M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-25.84M
Research Analysis: CRIS
View MoreCompany Insights: CRIS
CRIS does not have Company Insights